Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2775-2779

  Tsutani, Yasuhiro ^a,b   Ohara, Masahiro ^a   Suzuki, Takahisa ^a   Minami, Kazuhito ^a   Miyahara, Eiji ^a   Kameda, Akira ^a   Noso, Yoshihiro ^a  

^a Saiseikai Hiroshima Hospital   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Docetaxel; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; RECURRENCE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TEGAFUR;

EID: 69249192675     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Glimelius B, Ekström K, Hoffman K, Graf W, Sjöden PO, Haglund U et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997. (Pubitemid 27112884)
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993. (Pubitemid 23182046)
4. Pyrhönen S, Kuitunen T, Nyandoto P and Kouri M: Randomized comparison of fluorouracil, epidoxorabicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 58-91, 1995.
5. MacDonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D et al: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533-536, 1980. (Pubitemid 10015173)
6. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989. (Pubitemid 19220134)
7. Klein HO, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H and Gross R: High-dose MTX/5-FU and adriamycin for gastric cancer. Sem Oncol 10: 29-31, 1983.
8. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T et al: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616, 1994. (Pubitemid 24283097)
9. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer group. Oncology 58: 191-197, 2000. (Pubitemid 30189900)
10. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
11. Tanaka M, Obata T and Sasaki T: Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancer in vitro and in vivo. Eur J Cancer 32: 226-230, 1996. (Pubitemid 26090114)
12. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32: 248-254, 2002. (Pubitemid 43102808)
13. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S et al: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380-383, 1994. (Pubitemid 2119649)
14. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S et al: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 23: 341-344, 2000. (Pubitemid 32429142)
15. Wilke H, Vanhoefer U, Harstrick A, Achterrath W, Preusser P, Clemens MR et al: Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 17: 305 (abstr 1177), 1998.
16. Fume H and Taguchi T: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer. Ann Oncol 9(Suppl 4): 52 (abstr), 1998.
17. Yohsida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y et al: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006. (Pubitemid 43917349)
18. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H et al: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94: 1803-1808, 2006.
19. Yohsida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J et al: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1852, 2004.
20. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003. (Pubitemid 36962641)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
22. Van Den Neste E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C et al: A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 6: 64-71, 2000. (Pubitemid 30064977)
23. Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukushima M and Maehara Y: Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. Oncology 68: 130-137, 2005.
24. Wada, Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K et al: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119: 783-791, 2006. (Pubitemid 44055889)
25. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.